Get notified when TPST files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Going Concern (worsened) — Going-concern doubt persists; cash runway shortened from $21.5M to $1.8M, now under 12 months despite Factor credit line.
NASDAQ: TPST Tempest Therapeutics, Inc. 10-Q

Tempest cash drops to $1.8M; Factor credit line uncertain, strategic-sale process removed

Filed May 14, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 13, 2025 · ~1 min read

Key Changes

  • high

    Cash plunged from $21.5M to $1.8M year-over-year, with runway under 12 months. Going-concern doubt persists despite new Factor credit line.

    Risk Factors: Cash position verify on EDGAR →
  • high

    Closed Asset Acquisition in February 2026 with Factor credit line providing up to $20M over 18 months; $13.8M available but company warns of 'significant uncertainty' meeting access conditions.

    Risk Factors: Factor credit line verify on EDGAR →
  • high

    Strategic-alternatives process announced April 2025 (including potential merger, sale, or wind-down with MTS Health Partners as advisor) no longer disclosed, suggesting conclusion or abandonment.

    Risk Factors: Strategic alternatives verify on EDGAR →

1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (ADMT 10-K) is open in full — no account needed.

Partner

Trade TPST commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?

Source-verified from EDGAR · Narrative written by AI · May 25, 2026 · How we verify